SANAE
Tiger Aesthetics Medical, LLC · Decision date Aug 7, 2026
What did the FDA approve?
FDA records P020012/S051 as a supplement to PMA P020012, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 7, 2026.
FDA approval order statement
Approval to change the device trade name from Bellafill to SANAE
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Aug 7, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P020012/S051
- Regulatory pathway
- PMA supplement
- Applicant
- Tiger Aesthetics Medical, LLC
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Aug 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Tiger Aesthetics Medical, LLC
- Product code
- LMH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P020012/S051 received
Application receipt date recorded by FDA.
P020012/S052 · Related supplement
Bellafill Dermal Filler
P020012/S051 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P020012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P020012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Bellafill Dermal FillerP020012/S052 | Tiger Aesthetics Medical, LLC | PMA supplement | May 12, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Tiger Aesthetics Medical, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 555 E. N. Ln. Suite 5000, Bldg. D, Conshohocken, PA, 19428
Sources and methodology
- Original FDA record: P020012/S051
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




